



# JPEO-CBRND

Preventing the Worst by Providing the Best

## 2021 NDIA CBRN DEFENSE CONFERENCE & EXHIBITION

16-18 August 2021

**Dr. Jason W. Roos**

Joint Program Executive Officer for  
Chemical, Biological, Radiological and Nuclear Defense





# **CBDP MODERNIZATION FOCUS AREAS**

Modernize Biological Defense  
Integrated Early Warning  
Unencumber the Warfighter

# JPEO-CBRND

## CBDP MODERNIZATION FOCUS AREAS



### NEW PROGRAMS & INITIATIVES

#### MODERNIZE BIOLOGICAL DEFENSE

- Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) (FY22)
- Vaccine Acceleration by Modular Progression (VAMP) (FY22)
- 10 in 2 Interagency Antibody Challenge (FY22)
- Biological Defense Innovation Program (BDIP) (FY23)
- Plague Monoclonal Antibodies (PLG MAB) (FY23)



#### INTEGRATED EARLY WARNING

- CBRN Support to Command & Control (CSC2) (FY22)
- Wearable Monitors for Total Health Awareness (FY21)
- Robotics, Autonomy & Artificial Intelligence (AI) (FY21)

#### UNENCUMBERING THE WARFIGHTER

- **MODERNIZE THE MASK**
  - Ground Mask MWO (FY24)
  - Advanced System for Protection and Integrated Reduction of Encumbrances (ASPIRE) (FY25)
- **HAZARD MITIGATION**
  - Tactical Contamination Mitigation System (TCMS) (FY22)
  - Wide Area Decontamination System (WADS) (FY22)



# CONTACT

## Dr. Jason W. Roos

Joint Program Executive Officer for  
Chemical, Biological, Radiological and Nuclear Defense

---

410-436-4141

[jason.w.roos.civ@mail.mil](mailto:jason.w.roos.civ@mail.mil)

[www.jpeocbrnd.osd.mil](http://www.jpeocbrnd.osd.mil)

---

### Public Affairs Office

Phone: 410-436-9000

[usarmy.apg.dod-jpeo-cbrnd.mbx.jpeo-cbd-public-affairs-office@mail.mil](mailto:usarmy.apg.dod-jpeo-cbrnd.mbx.jpeo-cbd-public-affairs-office@mail.mil)

### Contracting

Alan Burket | 443-655-8608

Barry Sayer | 717-404-2650

### Online

[jpeocbrnd.osd.mil](http://jpeocbrnd.osd.mil)



@JPEOCBRND



# BACKUPS

# WHO WE ARE AND WHAT WE DO



## JPEO-CBRND

**MISSION:** Protect the Joint Force from weapons of mass destruction by generating affordable capabilities

**VISION:** A resilient Joint Force enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment; championed by innovative, agile, results-oriented acquisition professionals



COVID CLAIMS OVER 2 MILLION LIVES



SALISBURY NERVE AGENT POISONING



SYRIA SARIN ATTACK



KIM JONG-NAM ASSASSINATION



## CBDP

**MISSION:** Anticipate future threats and deliver capabilities that enable the Joint Force to fight and win in CB-contested environments

**VISION:** A Joint Force ready to fight and win in CB-contested environments through a coordinated effort designed to neutralize adversarial CB threats



# ARMY - A CRITICAL ENABLER OF THE NATIONAL COVID-19 RESPONSE

## PARTNERS

Success built on a Foundation of Partnerships with Government, Industry, Academia



ACADEMIA



INDUSTRY

## PEOPLE

Critical Subject Matter Experts supporting National Response

**13** Technical Subject Matter Experts Embedded in Leadership Roles with Federal Response Operation

**105+** Technical, Program Management, and Regulatory Subject Matter Experts Supporting Assisted Acquisition, Research & Development, and Ensuring Regulatory Compliance  
Does not include other Army support (e.g., Army Contracting Command, Army Support to Operation Warp Speed/Countermeasures Acceleration Group, etc.)

## PRODUCTS & PROCESSES

- Protecting and Saving Lives with the Full Spectrum of Medical Countermeasures
- Enabling Speed and Efficiency through Innovative and New Approaches

**COVID-19 SUPPORT & ASSISTED ACQUISITION** | **\$30B+** TOTAL OBLIGATED | **87** TOTAL CONTRACTS | **11+** TOTAL COUNTRIES

Leveraged Innovative Approaches and Full Range of DoD Authorities to Acquire Life-saving Vaccines, Therapeutics, and Diagnostics

**VACCINES**

**\$20.6B+** OBLIGATED | **9** CONTRACTS

Vaccines

**DIAGNOSTICS**

**\$1.4B+** OBLIGATED | **25** CONTRACTS

Instruments

Assays

Non Contact Thermometer

Medical Mobile Lab

**PPE**

**\$124M+** OBLIGATED | **9** CONTRACTS

Masks

Sanitizer

Gloves

**INTERNATIONAL DONATIONS**

**11+** COUNTRIES

Vaccines

International

**THERAPEUTICS**

**\$6.5B+** OBLIGATED | **12** CONTRACTS

Monoclonal Antibodies

**ENABLERS**

**\$432M+** OBLIGATED | **22** CONTRACTS

Syringes & Needles

Swabs

Strategic National Stockpile

Vials

**INDUSTRIAL BASE EXPANSION**

**\$1.0B+** OBLIGATED | **10** CONTRACTS

Industrial Base

**COVID-19 RESEARCH & DEVELOPMENT** | **\$1B+** TOTAL OBLIGATED | **49** TOTAL EFFORTS

Accelerated the Development of >25 Vaccines, Therapeutics, Diagnostics, and Enabling Technologies Across DHA, Army, and CDBP Funded Efforts

**VACCINES**

**\$520M+** OBLIGATED | **8** EFFORTS

Vaccines

Monoclonal Antibodies

**DIAGNOSTICS**

**\$42M+** OBLIGATED | **19** EFFORTS

Surveillance Stick

Assays

Wearables

**THERAPEUTICS**

**\$225M+** OBLIGATED | **14** EFFORTS

Plasma

Repurposed Drugs

**ENABLERS**

**\$295M+** OBLIGATED | **8** EFFORTS

Negatively Pressurized Conex

Clinical Trials



# JPEO-CBRND Focused on Learning from COVID Response to Continue Response and Better Prepare



## JPEO-CBRND Personnel and Partnerships



- Bench of highly skilled personnel necessary to enable surge and meet crisis
- Importance of having established trusted partnerships in place in time of need



## Support to Joint Force Readiness



- High interdependency between Joint Force readiness and global supply chain requires innovative market research, risk management, and funding / decisional flexibility in a constrained system
- In a crisis, require an operationally focused PEO where acquisition and operational communities work in parallel to effectively deploy novel technology



## Research, Development, Test, and Evaluation



- Take advantage of “peace time” to increase capacity and hone capabilities to accelerate delivery across PPE, diagnostics, treatment, and prevention in future pandemics / CBRN threats
  - e.g., clinical trial networks, priority access, refine platforms through MCM development
- Continuously evaluate and reprioritize efforts to redirect resources against the most critical needs as crisis and response evolve



## Rapid Response Acquisitions



- Established contracting mechanisms (e.g., MCDIC OTA) and cross-functional relationships expedite access to non-traditional industry partners
- Critical role of understanding incentives of non-traditional suppliers (e.g., Pharma) in negotiations
- Acquisition strategy informed by understanding of supply chain vulnerabilities to build resiliency